

Deborah T Blumenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6638981/publications.pdf>

Version: 2024-02-01

51
papers

1,648
citations

279798

23
h-index

302126

39
g-index

53
all docs

53
docs citations

53
times ranked

2926
citing authors

#	ARTICLE	IF	CITATIONS
1	Neurologic complications of immune checkpoint inhibitors. <i>Journal of Neuro-Oncology</i> , 2018, 137, 601-609.	2.9	126
2	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Neuro-Oncology</i> , 2017, 19, now208.	1.2	109
3	Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database. <i>Journal of Clinical Oncology</i> , 2009, 27, 733-739.	1.6	107
4	Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG. <i>Neuro-Oncology</i> , 2017, 19, 1119-1126.	1.2	107
5	Molecular-Based Recursive Partitioning Analysis Model for Glioblastoma in the Temozolomide Era. <i>JAMA Oncology</i> , 2017, 3, 784.	7.1	83
6	Pembrolizumab: first experience with recurrent primary central nervous system (CNS) tumors. <i>Journal of Neuro-Oncology</i> , 2016, 129, 453-460.	2.9	82
7	MRI radiomics analysis of molecular alterations in low-grade gliomas. <i>International Journal of Computer Assisted Radiology and Surgery</i> , 2018, 13, 563-571.	2.8	72
8	Delayed contrast extravasation MRI: a new paradigm in neuro-oncology. <i>Neuro-Oncology</i> , 2015, 17, 457-465.	1.2	66
9	Differentiation between vasogenic-edema versus tumor-infiltrative area in patients with glioblastoma during bevacizumab therapy: A longitudinal MRI study. <i>European Journal of Radiology</i> , 2014, 83, 1250-1256.	2.6	63
10	Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency. <i>Nature Medicine</i> , 2022, 28, 125-135.	30.7	53
11	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1-1.	1.6	52
12	A Phase III study of radiation therapy (RT) and O6-benzylguanine + BCNU versus RT and BCNU alone and methylation status in newly diagnosed glioblastoma and gliosarcoma: Southwest Oncology Group (SWOG) study S0001. <i>International Journal of Clinical Oncology</i> , 2015, 20, 650-658.	2.2	49
13	Investigating the Effect of Reirradiation or Systemic Therapy in Patients With Glioblastoma After Tumor Progression: A Secondary Analysis of NRG Oncology/Radiation Therapy Oncology Group Trial 0525. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 100, 38-44.	0.8	49
14	Management of malignant gliomas during pregnancy. <i>Cancer</i> , 2008, 113, 3349-3354.	4.1	48
15	Familiality in brain tumors. <i>Neurology</i> , 2008, 71, 1015-1020.	1.1	46
16	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. <i>Journal of Clinical Oncology</i> , 2021, 39, 2779-2790.	1.6	40
17	Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice. <i>Journal of Neuro-Oncology</i> , 2020, 148, 489-500.	2.9	38
18	Clinical utility and treatment outcome of comprehensive genomic profiling in high grade glioma patients. <i>Journal of Neuro-Oncology</i> , 2016, 130, 211-219.	2.9	35

#	ARTICLE	IF	CITATIONS
19	Classification of High-Grade Glioma into Tumor and Nontumor Components Using Support Vector Machine. <i>American Journal of Neuroradiology</i> , 2017, 38, 908-914.	2.4	35
20	Differentiation between vasogenic edema and infiltrative tumor in patients with high-grade gliomas using texture patch-based analysis. <i>Journal of Magnetic Resonance Imaging</i> , 2018, 48, 729-736.	3.4	34
21	Short delay in initiation of radiotherapy for patients with glioblastoma-effect of concurrent chemotherapy: a secondary analysis from the NRG Oncology/Radiation Therapy Oncology Group database. <i>Neuro-Oncology</i> , 2018, 20, 966-974.	1.2	33
22	Differentiation between treatment-related changes and progressive disease in patients with high grade brain tumors using support vector machine classification based on DCE MRI. <i>Journal of Neuro-Oncology</i> , 2016, 127, 515-524.	2.9	30
23	Stereotactic radiosurgery (SRS) in high-grade glioma: judicious selection of small target volumes improves results. <i>Journal of Neuro-Oncology</i> , 2016, 126, 551-557.	2.9	24
24	RTOG 0825: Phase III double-blind placebo-controlled trial evaluating bevacizumab (Bev) in patients (Pts) with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 1-1.	1.6	24
25	Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature. <i>Journal of Clinical Neuroscience</i> , 2017, 37, 51-53.	1.5	23
26	Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. <i>Neuro-Oncology</i> , 2020, 22, 694-704.	1.2	23
27	Optimal timing of chemoradiotherapy after surgical resection of glioblastoma: Stratification by validated prognostic classification. <i>Cancer</i> , 2020, 126, 3255-3264.	4.1	19
28	Effect of cannabis on oxaliplatin-induced peripheral neuropathy among oncology patients: a retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592199020.	3.2	19
29	Early Biomarkers from Conventional and Delayed-Contrast MRI to Predict the Response to Bevacizumab in Recurrent High-Grade Gliomas. <i>American Journal of Neuroradiology</i> , 2016, 37, 2003-2009.	2.4	18
30	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA2010-LBA2010.	1.6	18
31	Human cerebral blood volume measurements using dynamic contrast enhancement in comparison to dynamic susceptibility contrast MRI. <i>Neuroradiology</i> , 2015, 57, 671-678.	2.2	16
32	Calcification in high grade gliomas treated with bevacizumab. <i>Journal of Neuro-Oncology</i> , 2015, 123, 283-288.	2.9	14
33	Surgery for Recurrent High-Grade Glioma After Treatment with Bevacizumab. <i>World Neurosurgery</i> , 2018, 110, e727-e737.	1.3	14
34	Flashes of light-radiation therapy to the brain. <i>Radiotherapy and Oncology</i> , 2015, 116, 331-333.	0.6	12
35	Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis. <i>Neuro-Oncology Practice</i> , 2021, 8, 426-440.	1.6	11
36	Independently validated sex-specific nomograms for predicting survival in patients with newly diagnosed glioblastoma: NRG Oncology RTOG 0525 and 0825. <i>Journal of Neuro-Oncology</i> , 2021, 155, 363-372.	2.9	11

#	ARTICLE	IF	CITATIONS
37	Assessment of neuropathic pain in cancer patients. <i>Current Pain and Headache Reports</i> , 2009, 13, 282-287.	2.9	9
38	Repeatability of dynamic contrast enhanced vp parameter in healthy subjects and patients with brain tumors. <i>Journal of Neuro-Oncology</i> , 2018, 140, 727-737.	2.9	9
39	Optimization of DCE-MRI protocol for the assessment of patients with brain tumors. <i>Magnetic Resonance Imaging</i> , 2016, 34, 1242-1247.	1.8	6
40	Molecular predictors of outcome and response to bevacizumab (BEV) based on analysis of RTOG 0825, a phase III trial comparing chemoradiation (CRT) with and without BEV in patients with newly diagnosed glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, LBA2010-LBA2010.	1.6	6
41	Impact of contemporary regimens on the outcomes and toxicity of primary CNS lymphoma: a single-center retrospective analysis of 73 patients. <i>Journal of Neuro-Oncology</i> , 2021, 151, 211-220.	2.9	5
42	Genome-wide analysis of high-risk primary brain cancer pedigrees identifies PDXDC1 as a candidate brain cancer predisposition gene. <i>Neuro-Oncology</i> , 2021, 23, 277-283.	1.2	3
43	Ofranogene obadenovec (VB-111), an anti-cancer gene therapy in combination with bevacizumab to improve overall survival compared to bevacizumab monotherapy in patients with rGBM: A phase 2 historically controlled trial.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2074-2074.	1.6	3
44	IMCT-01PEMBROLIZUMAB: FIRST EXPERIENCE WITH RECURRENT PRIMARY CENTRAL NERVOUS SYSTEM (CNS) TUMORS. <i>Neuro-Oncology</i> , 2015, 17, v107.1-v107.	1.2	2
45	Verification of statistical oncological endpoints on encrypted data: Confirming the feasibility of real-world data sharing without the need to reveal protected patient information.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18725-e18725.	1.6	1
46	Safety of tumor treating fields and concomitant radiotherapy for newly diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, e14078-e14078.	1.6	1
47	HOUT-28. CLINICAL EXPERIENCE WITH TUMOR TREATING FIELDS (TTFIELDS, OPTUNE®) IN ISRAEL - PATIENT ACCEPTANCE AND SAFETY. <i>Neuro-Oncology</i> , 2018, 20, vi119-vi119.	1.2	0
48	An independently validated nomogram for individualized estimation of survival among patients with newly diagnosed glioblastoma: NRG oncology/RTOG 0525 and 0825.. <i>Journal of Clinical Oncology</i> , 2016, 34, 2007-2007.	1.6	0
49	Treatment through progression with ofranogene obadenovec (VB-111), an anti-cancer viral therapy, significantly attenuates tumor growth in recurrent GBM: Individual phase 2 patient data.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2055-2055.	1.6	0
50	Post-marketing safety surveillance of tumor treating fields (TTFields) in patients with high-grade glioma in clinical practice.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2542-2542.	1.6	0
51	RARE-17. SURVIVAL BENEFIT FOR INDIVIDUALS WITH CONSTITUTIONAL MISMATCH REPAIR DEFICIENCY SYNDROME AND BRAIN TUMORS WHO UNDERGO SURVEILLANCE PROTOCOL. A REPORT FROM THE INTERNATIONAL REPLICATION REPAIR CONSORTIUM. <i>Neuro-Oncology</i> , 2020, 22, iii445-iii446.	1.2	0